Participated · Series C · May 2026

Cerevance uses a proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform to identify drug targets expressed in specific human brain cell types. Its lead investigational candidate, solengepras (CVN424), is a once-daily oral therapy being evaluated in the pivotal Phase 3 ARISE trial, which is fully enrolled with 341 patients. ARISE is a randomized, double-blind, placebo-controlled study assessing solengepras as an adjunctive therapy in patients with motor fluctuations; topline data are expected at the end of Q3 2026. The company also is developing CVN293, a selective oral inhibitor targeting THIK1 (KCNK13). Cerevance announced an oversubscribed $20 million Series C to fund operations through the ARISE readout and to advance its pipeline, extending runway into mid-2027. The company is clinical-stage and based in Boston.

Participated · Series A · Sep 2025

Optain Health offers a portable robotic retinal camera, integrated AI workflows, and teleophthalmology to enable rapid, non‑invasive screening for eye diseases and systemic risk (oculomics). Its platform detects diabetic retinopathy, glaucoma, age‑related macular degeneration, and assesses cardiovascular risk while delivering teleophthalmology grading in the U.S. The company was co‑created in 2023 by Aegis Ventures and builds on more than a decade of Australian R&D led by Professor Mingguang He. Optain is expanding deployments into primary care, optometry, and health systems with the goal of closing care gaps and improving outcomes with minimal specialist staffing. The company uses teleophthalmology services in the U.S.; its automated disease detection software is not for sale in the U.S. Optain is scaling globally with investments in Australian R&D to support expansion outside the U.S. Optain develops AI-enabled software and hardware that noninvasively diagnose eye and systemic health conditions in real time using photos of the eye. Its portable retinal camera and accompanying AI software enable clinicians to screen for more than 140 eye and systemic conditions at early stages. The company is led by CEO Jeff Dunkel and positions the eye as a gateway to monitor whole-person health. Optain's approach is based on over a decade of research by Professor Mingguang He of the University of Melbourne and the Centre for Eye Research Australia. The company traces its roots to Australian-founded Eyetelligence (launched in 2019), whose clinically validated and regulatory-approved AI products are commercialized across Australia, New Zealand, Europe, Japan and the Middle East. Optain intends to use recent seed funding to expand operations and development efforts.

Participated · Series B · Sep 2021

Xealth is a Seattle-based company that develops digital health enablement solutions for health systems. Its platform allows providers to prescribe and monitor digital health content, apps, and services as easily as medications. The platform incorporates custom data and analytics so health systems can track, analyze, and evaluate digital health use through its integration platform. Led by CEO Mike McSherry, Xealth reports 12 million orders sent, 100,000 providers engaged, and three million patients reached to date. The company received an investment from Morningside Ventures and intends to use the funds to expand operations and its development efforts. The amount and instrument of the investment were not disclosed in the announcement. Xealth provides a platform that centralizes integration, prescribing, monitoring and governance for digital health tools within clinician workflows. The platform is tightly integrated with EHRs and has full integrations with the largest EHR vendors. It is available to more than 100,000 physicians and its deployments demonstrate a 50–80% reduction in integration and deployment costs while driving substantial patient engagement. Xealth is backed by health systems and strategic investors, including Cerner, Novartis, Philips, ResMed, McKesson Ventures, Threshold Ventures and LRV Health. The company plans to use the new funding to roughly double its team and to fund product innovation, including enhancements to its intelligence engine to better match tools to patients and scale deployments across the U.S. Spun out of Providence St. Joseph Health in 2017 and based in Seattle, Xealth has raised $52.6 million to date. Xealth provides a platform that enables health systems to organize, integrate, deploy and activate digital health tools and programs. Through the platform, clinicians can find and order digital health tools directly from the EHR workflow, send those digital orders to patients' smartphones or desktops, monitor patient engagement and analyze the effects of more engaged patients. The company raised an additional $3M in its Series A, bringing the round to $14M total, and intends to use the funds to advance development and deployment of its platform for digital health programs. Xealth spun out of Providence St. Joseph Health in 2017 and is led by CEO Mike McSherry; it is based in Seattle, Washington. It works with health systems including UPMC, the Froedtert and the Medical College of Wisconsin health network, Duke Health and other leading health systems. Xealth is a digital prescribing platform that enables clinicians to integrate, prescribe and monitor digital health tools for patients from their EHR workflows. Its platform supports patient education, online third-party apps and programs, device monitoring, and non-clinical services such as ride shares, food delivery and e-commerce recommendations. Care teams and physicians can monitor patient engagement and analyze the effects of more engaged patients. Originally incubated and spun out of Providence St. Joseph Health in 2017 and led by CEO Mike McSherry, the company is based in Seattle, WA. Xealth works with health systems including UPMC, the Froedtert and the Medical College of Wisconsin health network, Baylor Scott and White, and Duke. The company raised $11m in a Series A to accelerate expansion of its platform. Xealth is launching a digital prescribing and analytics platform that lets physicians and clinicians prescribe and track educational health content, disease-management apps, and monitoring devices directly from their EMR charting interface. The platform aggregates and filters a variety of content sources into a care provider’s existing EMR workflow, simplifying creation of a customized patient experience. Clinicians can discuss digital tools during appointments, track patient usage afterward, and schedule reminders to encourage engagement. Patients access prescribed digital health tools through their health system’s secure patient portal. Xealth was founded in 2016 by Mike McSherry and was incubated within Providence’s Digital Innovation Group. The company has raised $8.5M to support launch and expansion with participating health systems planning broader integration and use of third-party digital solutions.

Led · Seed · Aug 2021

Novasenta is a biotechnology company focused on the discovery and validation of novel therapeutic targets to develop cancer therapies. It develops antibody-based therapeutics and has built a proprietary single-cell RNA–based analysis platform applied to high-quality human tumor samples, combined with advanced data mining and target validation capabilities. The company’s pipeline includes three programs representing next-generation immuno-oncology targets and drug candidates. Novasenta plans to use recent funding to advance its pipeline programs, expand its computational platforms for target discovery, and continue recruiting top talent. The company was co-founded in late 2018 by Robert Ferris, M.D., Ph.D., Dario Vignali, Ph.D., and Greg Delgoffe, Ph.D., all affiliated with the UPMC Hillman Cancer Center and the University of Pittsburgh. Novasenta focuses on developing cancer immunotherapies by targeting the tumor microenvironment. It leverages a proprietary platform that combines cell analyses, animal models and machine learning to discover novel drug targets. The company is currently focused on T-cell targets and aims to launch its first clinical trial by the end of 2023. Novasenta was founded in 2018 by Dr. Robert Ferris, Dario Vignali and Greg Delgoffe, who work at UPMC Hillman Cancer Center and the University of Pittsburgh, and is based in Pittsburgh. UPMC invested $20 million in a seed round through its innovation and venture capital arm, UPMC Enterprises. The company was incubated by UPMC Enterprises in collaboration with the University of Pittsburgh and is led by CEO Mani Mohindru, who previously held leadership roles at CereXis and Cara Therapeutics. The article notes the global oncology drugs market was valued at about $128 billion in 2019 and is projected to reach $222 billion by 2027, underscoring a crowded but growing competitive landscape.

Led · Seed · Oct 2020

Abridge builds AI scribe technology that automates medical notes and integrates with Epic Systems. The company says its technology is used by over 150 of the largest U.S. health systems. In Q1 Abridge reported $117 million in contracted annual recurring revenue (a metric that includes signed recurring contracts, including customers not yet onboarded). It is expanding into converting medical notes from patient appointments into AI-powered medical codes, a move that positions it against startups like CodaMetrix and features from Epic. Abridge is widely considered a leader in the AI-powered medical scribe market due to early entry and Epic integration. The company was founded by cardiologist Shiv Rao and is seven years old. Abridge provides an enterprise-grade generative AI platform that transforms medical conversations into clinically useful and billable documentation at the point of care. The platform maps AI-generated summaries to source data using Linked Evidence to make outputs auditable and verifiable. It integrates deeply with EHRs, supports 28+ languages and 50+ specialties, and is used across outpatient, emergency department, and inpatient settings. Abridge says it has been deployed in more than 100 health systems, with enterprise implementations at Duke Health, Johns Hopkins, Mayo Clinic, UNC Health and others, representing tens of thousands of clinicians. The company recently introduced a Contextual Reasoning Engine to incorporate retrospective encounters, revenue-cycle rules, and clinician preferences to produce more comprehensive, billable notes and capture orders for EHRs. The Series D funding will support continued AI research and commercial growth to broaden applications and reduce clinician administrative burden. Abridge builds an AI-powered virtual medical scribe and clinical note-taking product that records patient encounters and generates editable visit notes. The company began with a free smartphone transcription app whose usage helped train its proprietary medical LLM on thousands of doctor–patient conversations. Its virtual scribe supports 14 foreign languages and has secured a right to be integrated inside Epic so notes can appear directly in the EHR for clinician verification. Large health systems are buying multi‑thousand-seat licenses, and Abridge has been announcing a new health system customer nearly every week since the start of 2024 (customers named include University of Chicago, Sutter, Yale, Lee Health, Christus and Emory). The company says its product materially reduces physicians’ administrative burden and has been described by customers as “life-changing” and “magical.” Abridge faces competition from incumbents and other AI scribe vendors, and observers note the open question of whether general foundation models could narrow its lead over time. Abridge builds generative AI for clinical documentation, transforming patient–clinician conversations into structured clinical notes in real time with deep EMR integrations. The platform uses Linked Evidence and auditable AI that maps AI-generated summaries to ground truth to help providers trust and verify outputs. Its stack orchestrates language identification, transcription, alignment, diarization, summarization, and verification models to produce and validate notes within seconds, reducing clinician latency from minutes to seconds. Abridge is collaborating with NVIDIA to leverage NVIDIA compute resources, foundation models, and deployment expertise to scale deployments across clinicians in the U.S. and eventually internationally. The company emphasizes research into clinically specialized foundation models, medical speech and language technology, and responsible AI. Abridge was founded in 2018 and is based in Pittsburgh, Pa. Abridge builds AI that captures and summarizes spoken patient–clinician conversations, converting them into structured clinical note drafts in real time. Its audio and ambient AI solutions integrate with EHR systems and allow patients to review notes, medication instructions, treatments, and follow-ups. The company highlights peer-reviewed R&D in medical conversation AI and user experience design. Abridge’s tools support both in-person and telemedicine appointments and aim to free clinicians from clerical work so they can focus on patients. The company says it has spent the last five years developing its technology. SCAN Group began offering Abridge’s service as a supplemental benefit in 2021.